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A B S T R A C T
Aim. – To explore if efficacy and safety findings for insulin glargine 300 U/mL (Gla-300) versus insulin
glargine 100 U/mL (Gla-100), observed over 6 months in insulin-naı¨ve people with type 2 diabetes, are
maintained after 12 months.
Methods. – EDITION 3 was a phase 3a, randomized, multicentre, open-label, parallel-group, treat-to-
target study of once-daily Gla-300 versus Gla-100 (target fasting self-monitored plasma glucose,
4.4–5.6 mmol/L [80–100 mg/dL]). Participants completing the initial 6-month treatment phase
continued their previously allocated basal insulin.
Results. – Of 878 participants randomized, 337/439 (77%) and 314/439 (72%) assigned to Gla-300 and
Gla-100, respectively, completed 12 months of treatment. Improved glycaemic control was sustained
until 12 months in both treatment groups, with similar reductions in HbA1c from baseline to month 12
(difference: 0.08 [95% confidence interval (CI): 0.23 to 0.07] % or 0.9 [2.5 to 0.8] mmol/mol).
Relative risk of experiencing  1 confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic event
with Gla-300 versus Gla-100 was 0.86 (95% CI: 0.69 to 1.07) at night and 0.92 (0.82 to 1.03) at any time of
day. For events with a glycaemic threshold of < 3.0 mmol/L (< 54 mg/dL) these numbers were 0.76
(0.49 to 1.19) and 0.66 (0.50 to 0.88). A similar pattern was seen for documented symptomatic events. No
between-group differences in adverse events were identified.
Conclusion. – Over 12 months, Gla-300 treatment was as effective as Gla-100 in reducing HbA1c in
insulin-naı¨ve people with type 2 diabetes, with lower overall risk of hypoglycaemia at the < 3.0 mmol/L
threshold.
C 2017 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Although people with type 2 diabetes initially achieve glycaemic
control with lifestyle modifications followed by non-insulin anti-
hyperglycaemic agents (AHAs), as the condition progresses most
will eventually require insulin therapy to maintain control
[1]. Several insulin treatment protocols are available, but physio-
logical and psychosocial barriers to starting and continuing insulin,
including concerns regarding hypoglycaemia, weight gain and the
lack of flexibility [2–4], may lead to delay in beginning insulin; thesend hypoglycaemia with insulin glargine 300 U/mL versus insulin
month results from the EDITION 3 trial. Diabetes Metab (2017),
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better glycaemic control through appropriate insulin dose titration.
Insulin glargine 300 U/mL (Gla-300) is characterized by flatter
pharmacokinetic (PK) and pharmacodynamic (PD) profiles with
longer duration of action compared with insulin glargine 100 U/mL
(Gla-100), resulting in effective blood glucose control beyond
24 hours [5]. The phase 3a EDITION programme was designed to
determine whether the PK and PD profiles of Gla-300 translated
into clinical benefit in different populations of people with
diabetes. Studies in type 2 diabetes using basal and meal-time
insulin (EDITION 1) [6] or basal insulin (and non-insulin AHAs)
(EDITION 2) [7] demonstrated that Gla-300 provided comparable
glycaemic control to Gla-100, but with a lower rate of hypo-
glycaemia over 6 months. Over 12 months, sustained glycaemic
control and lower hypoglycaemia risk with Gla-300 were also
found in prior insulin-treated people [8,9].
EDITION 3 [10] investigated the efficacy and safety of Gla-300
versus Gla-100 in insulin-naı¨ve people with type 2 diabetes whose
blood glucose levels were inadequately controlled with non-
insulin AHAs. In line with results from EDITION 1 and 2, the
6-month EDITION 3 results demonstrated equivalent glycaemic
control with Gla-300 and Gla-100, associated with a significantly
lower risk of nocturnal (00:00–05:59 h) confirmed ( 3.9 mmol/L
[ 70 mg/dL]) or severe hypoglycaemia. Here, we present the
12-month efficacy and safety results from EDITION 3.
Materials and methods
Study design and participants
EDITION 3 was a multicentre, randomized, open-label, two-
arm, parallel-group, treat-to-target phase 3a study conducted in
2012–2013, involving 878 participants with type 2 diabetes.
Details of the study design have been described previously
[10]. Briefly, adults  18 years of age with type 2 diabetes for at
least 1 year prior to screening, having used non-insulin AHAs for at
least 6 months prior to screening and being insulin naı¨ve, were
randomized 1:1 to once-daily Gla-300 (using a modified Tactipen1
injector [Sanofi, Paris, France]) or Gla-100 (using a SoloSTAR1 pen
[Sanofi]) for a period of 12 months. Exclusion criteria included
HbA1c< 7.0% (< 53 mmol/mol) or > 11.0% (> 97 mmol/mol) at
screening. Any non-insulin AHAs not approved for combination with
insulin, and/or sulfonylureas or glinides, were discontinued at baseline.
Daily basal insulin was started at 0.2 U/kg body weight, and
then adjusted once weekly, aiming for a fasting self-monitored
plasma glucose (SMPG) of 4.4–5.6 mmol/L (80–100 mg/dL) in the
absence of hypoglycaemia (Table S1; see supplementary material
associated with this article online). If, after dose titration,
laboratory-measured fasting plasma glucose (FPG) or HbA1c were
above the target without reasonable explanation, and if appropri-
ate action failed to correct this, intensification of therapy was to be
considered, namely rescue medication chosen by investigator
discretion. Participants who completed the 6-month treatment period
continued to receive either Gla-300 or Gla-100, according to initial
randomization, for a further predefined 6-month extension phase.
Appropriate local or national ethics committees approved the
study protocol. The study was registered with ClinicalTrials.gov
(NCT01676220) and was conducted according to Good Clinical
Practice and the Declaration of Helsinki.
Outcomes
The primary efficacy endpoint in EDITION 3, change in HbA1c
from baseline to month 6, has been previously reported [10]. For
the 12-month on-treatment period, the efficacy outcomes were:
change from baseline to month 12 in HbA1c, FPG, pre-breakfastPlease cite this article in press as: Bolli GB, et al. Glycaemic control a
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http://dx.doi.org/10.1016/j.diabet.2017.04.007SMPG, 8-point SMPG profiles and basal insulin dose. Safety/
tolerability outcomes included the percentage of participants
experiencing  1 hypoglycaemic event, annualized rates of hypo-
glycaemic events, change from baseline to month 12 in body
weight, and the occurrence of other adverse events (AEs). Other
safety information such as clinical laboratory data and vital signs
were recorded throughout the study.
Hypoglycaemic events were categorized based on American
Diabetes Association definitions [11]:
 severe hypoglycaemia;
 documented symptomatic hypoglycaemia (typical symptoms of
hypoglycaemia and a measured plasma glucose concentration
of  3.9 mmol/L [ 70 mg/dL]);
 and asymptomatic hypoglycaemia (measured plasma glucose
concentration of  3.9 mmol/L [ 70 mg/dL] in the absence of
typical symptoms of hypoglycaemia).
The confirmed (with or without symptoms) and severe categories
were combined and analysed as ‘confirmed or severe’ hypoglycaemia.
In addition, hypoglycaemic events with a plasma glucose measure-
ment of < 3.0 mmol/L (< 54 mg/dL) were analysed.
Hypoglycaemia was assessed as events occurring during the
night (00:00–05:59 h) and at any time of day (24 h), and also by the
following subgroups: age (< 65 years; 65–75 years;  75 years),
randomization stratum of HbA1c at screening (< 8.0%;  8.0%), BMI
at baseline (< 30 kg/m2;  30 kg/m2), duration of diabetes
(< 10 years;  10 years). An additional post hoc exploratory
analysis was by prior sulfonylurea use (within the 3 months prior
to screening or within the run-in period).
Bicomposite efficacy endpoints (post hoc, exploratory) were
also assessed, defined as the percentage of participants achieving
HbA1c target (< 7.0%) at month 12 without hypoglycaemia
(confirmed or severe, or documented symptomatic, at both
glycaemic thresholds) at night (00:00–05:59 h) and at any time
of day (24 h) over 12 months of treatment.
Participant-reported outcomes (PRO) included treatment satis-
faction (using the Diabetes Treatment Satisfaction Questionnaire
[DTSQs, status version]) [12–14], health-related quality of life
(using the EuroQol 5 Dimensions [EQ-5D] questionnaire) [15], and
behaviours and worries related to fear of hypoglycaemia (using the
hypoglycaemia fear scale [HFS-II]) [16].
Data analysis and statistics
The efficacy and PRO analyses used the modified intent-to-treat
(mITT) population, namely all randomized participants who
received  1 dose of study insulin and had both a baseline
and  1 post-baseline efficacy assessment. Safety analyses used
the safety population, comprising all participants randomized and
exposed to  1 dose of study insulin.
For all efficacy outcomes other than change in basal insulin
dose, 8-point SMPG, and pre-breakfast SMPG, a mixed effects
model for repeated measures (MMRM) analysis was conducted.
Change in body weight was assessed using an analysis of
covariance (ANCOVA) model. Bicomposite efficacy endpoints were
compared using a Cochran–Mantel–Haenszel method stratified by
randomization strata of screening HbA1c (< 8.0 and  8.0%). AEs
were analysed descriptively and coded using the Medical
Dictionary for Regulatory Activities (MedDRA) system.
The Cochran–Mantel–Haenszel method was used to analyse the
percentage of participants with at least one hypoglycaemic event,
and an overdispersed Poisson regression model using treatment
period (expressed in years) as offset and stratified by randomization
strata of screening HbA1c (< 8.0 and  8.0%) was used to analyse the
hypoglycaemic event rate.nd hypoglycaemia with insulin glargine 300 U/mL versus insulin
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Study population
As previously reported [10], 878 participants were randomized
to receive Gla-300 (n = 439) or Gla-100 (n = 439) (Fig. 1); of these,
435 and 438 respectively, formed the safety population, while
432 and 430 participants, comprised the mITT population. Baseline
characteristics have been reported previously, and were similar
between-treatment groups [10]. The discontinuation rate was
similar in the Gla-300 (n = 84; 19%) and Gla-100 (n = 102; 23%)
groups, with 337 and 314 participants completing the 12-month
study without the need for rescue therapy. The majority of
discontinuations in the Gla-300 (n = 57) and Gla-100 (n = 78)
groups were made at the participant’s request. Perceived lack of
efficacy accounted for the discontinuation of three participants
(0.7%) in the Gla-300 group and one participant (0.1%) in the
Gla-100 group. Rescue therapy was required by 15 (3.4%) and 26
(5.9%) participants in the Gla-300 and Gla-100 groups, respective-
ly, more frequently being a fast-acting insulin analogue in both
treatment groups (Gla-300 n = 12; Gla-100 n = 19).
Glycaemic response
The improvement in glycaemic control observed at 6 months,
measured by HbA1c (Fig. 2A) and FPG (Fig. 2B), was maintained to
month 12 and was similar with the two treatments. At month 12,
mean (SD) HbA1c was 7.13 (1.00) % (54.4 [10.9] mmol/mol) with
Gla-300 and 7.24 (0.97) % (55.6 [10.6] mmol/mol) with Gla-100.
The least squares (LS) mean difference in HbA1c change from
baseline to month 12 for Gla-300 versus Gla-100 was 0.08878 random 
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to 0.8] mmol/mol)) (Table S2; see supplementary material
associated with this article online). LS mean difference in FPG
change for Gla-300 versus Gla-100 was 0.07 (95% CI: 0.26 to
0.40) mmol/L (1.32 [95% CI: 4.62 to 7.26] mg/dL) (Table S2; see
supplementary material associated with this article online).
Pre-breakfast SMPG decreased in both treatment groups, with
the largest decrease occurring during the first 12 weeks. Mean (SD)
pre-breakfast SMPG levels were very similar in the two treatment
groups at month 12: Gla-300, 6.19 (1.21) mmol/L (111.5
[21.8] mg/dL); Gla-100, 6.18 (1.37) mmol/L (111.4 [24.7] mg/
dL). Eight-point SMPG profiles decreased markedly for both Gla-
300 and Gla-100 during the study, and at month 12 the plasma
glucose profiles were similar in the two treatment groups (Fig. 2C).
Insulin dose
Daily basal insulin dose increased up to month 12 in both
treatment groups, but to a greater extent in the Gla-300 group
(Fig. 2D). The mean (SD) basal insulin dose at month 12 was 0.67
(0.33) U/kg/day in the Gla-300 group and 0.56 (0.27) U/kg/day in
the Gla-100 group (20% higher with Gla-300). Forty-five percent of
the dose difference at month 12 was reached by week 12.
Hypoglycaemia
Nocturnal (00:00–05:59 h) confirmed ( 3.9 mmol/L [ 70 mg/dL]) or
severe hypoglycaemia
The percentage of participants experiencing  1 nocturnal
confirmed or severe hypoglycaemic event over the 12-month
treatment period was 25% with Gla-300 and 29% with Gla-100ized
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of participants needed to be treated in order to prevent one
participant from experiencing such an event over 1 year was
24. Annualized rates of nocturnal confirmed or severe hypo-
glycaemic events were similar in the two insulin groups over the
12-month treatment period (Gla-300 1.33 events/participant-year
vs. Gla-100 1.36 events/participant-year; RR: 0.98 [95% CI: 0.69 to
1.40]) (Fig. 3B).
Any time of day confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe
hypoglycaemia
Over 12 months, the percentage of participants who
experienced  1 confirmed or severe hypoglycaemic event occur-
ring any time of day was 56% with Gla-300 and 61% with Gla-100
(RR: 0.92 [95% CI: 0.82 to 1.03]) (Fig. 3A). The number of
participants needed to be treated in order to prevent one
participant from experiencing  1 confirmed or severe hypo-
glycaemic event at any time of day over 1 year was 21. Annualized
rates of hypoglycaemic events were similar with Gla-300 and
Gla-100 (7.14 events/participant-year vs. 8.11 events/participant-
year; RR: 0.88 [95% CI: 0.70 to 1.11]) (Fig. 3B).
Severe hypoglycaemia
There were no reports of nocturnal (00:00–05:59 h) severe
hypoglycaemia with Gla-300, while three participants (0.7%)
reported such events with Gla-100. Six participants in the
Gla-300 group (1.4%) and nine in the Gla-100 group (2.1%)
reported severe hypoglycaemia at any time of day (24 h).
Other definitions of hypoglycaemia
The percentage of participants experiencing  1 documented
symptomatic ( 3.9 mmol/L [ 70 mg/dL]) hypoglycaemic eventPlease cite this article in press as: Bolli GB, et al. Glycaemic control a
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Gla-300 and Gla-100 at night (00:00–05:59 h), and 39% and 44% at
any time of day (24 h) (Fig. 3A). Annualized rates of the any time of
day events showed a statistically significant 27% reduction in rate
with Gla-300 versus Gla-100 at any time of day (24 h) (Fig. 3B).
Using the more stringent glycaemic threshold (< 3.0 mmol/L
[< 54 mg/dL]) for confirmed or severe hypoglycaemia, 7.1% and
9.4% of participants receiving Gla-300 and Gla-100, respectively,
reported nocturnal (00:00–05:59 h) hypoglycaemia over
12 months (Fig. 3A; RR: 0.76 [95% CI: 0.49 to 1.19]), while 14%
and 22% of participants reported hypoglycaemia at any time of day
(24 h) (RR: 0.66 [0.50 to 0.88]; for documented symptomatic
hypoglycaemia, RR: 0.65 [0.47 to 0.90]) (Fig. 3A). Annualized rates
at this lower glycaemic threshold were also numerically lower, at
night (00:00–05:59 h) and at any time of day (24 h), with Gla-300
than with Gla-100 for confirmed or severe hypoglycaemia, and for
documented symptomatic hypoglycaemia (Fig. 3B).
Pattern of hypoglycaemia by time of day (24 h)
The percentage of participants experiencing  1 confirmed
( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic event was
lower in the Gla-300 group than in the Gla-100 group throughout
most of the day (Fig. 4), suggesting that Gla-300 reduced the risk of
hypoglycaemia beyond the protocol-defined nocturnal period
(although no statistical testing of differences was performed).
Hypoglycaemia by subgroup
The percentage of participants with  1 confirmed
( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic event at
any time of day (24 h) over 12 months of treatment was numerically
lower with Gla-300 than Gla-100 for all subgroups (age, HbA1c
stratum, BMI at baseline, and duration of diabetes) (Fig. 5).nd hypoglycaemia with insulin glargine 300 U/mL versus insulin
month results from the EDITION 3 trial. Diabetes Metab (2017),
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Relative risk (95% CI) 
0.4 1.81.0
Safety
population
(n)
Relative risk
Gla-300 vs.
Gla-100 (95% CI)
Overall 873 0.92 (0.82  to 1.03)
Age <65  years 649 0.90 (0.79  to 1.03)
≥65  to <75 years 188 0.95 (0.78 to 1.16)
≥75 years 36 0.98 (0.57 to 1.66)
HbA1c randomization
stratum
<8.0 % 282 0.98 (0.81 to 1.18)
≥8.0 % 591 0.89 (0.78 to 1.02)
BMI <30 kg/m2 315 0.84 (0.72 to 0.99)
≥30 kg/m2 558 0.97 (0.83 to 1.13)
Diabetes duration* <10 years 497 0.97 (0.82 to 1.15)
≥10 years 369 0.86 (0.75 to 0.99)
Favours
Gla-100
Favours
Gla-300
Fig. 5. Relative risk of participants experiencing at least one confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemic event at any time of day (24 h) by subgroup
during the 12-month on-treatment period. Safety population. BMI: body mass index.
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CI: 0.72 to 0.99), while for those with a diabetes duration
of  10 years the RR was 0.86 (95% CI: 0.75 to 0.99). No
heterogeneity of treatment effect across subgroups was observed.
Similar results were observed for the percentage of participants
with  1 confirmed ( 3.9 mmol/L [ 70 mg/dL]) or severe hypo-
glycaemic event at night (00:00–05:59 h) (data not shown). In
addition, no heterogeneity of treatment effect was observed for the
post hoc analysis of hypoglycaemia (percentage of participants
with  1 confirmed [ 3.9 mmol/L ( 70 mg/dL)] or severe event at
night or at any time of day [24 h]) by sulfonylurea subgroup.
Bicomposite endpoints
The percentage of participants reaching an HbA1c target
of < 7.0% without nocturnal (00:00–05:59 h) confirmed
( 3.9 mmol/L [ 70 mg/dL]) or severe hypoglycaemia was 23%
in the Gla-300 group versus 19% in the Gla-100 group (Responder
Ratio: 1.24 [95% CI: 0.96 to 1.61]). For those without nocturnal
documented symptomatic ( 3.9 mmol/L [ 70 mg/dL]) hypogly-
caemia, the percentage of participants was 28% versus 24%
(Responder Ratio 1.19 [95% CI: 0.96 to 1.49]) (Table S3; see
supplementary material associated with this article online).
Similar differences between Gla-300 and Gla-100 were observed
for hypoglycaemia at any time of day (24 h), and hypoglycaemia
confirmed at the lower glycaemic threshold of < 3.0 mmol/L
(< 54 mg/dL) (Table S3; see supplementary material associated
with this article online). In these analyses the between-treatment
difference did not reach statistical significance, except for the
percentage of participants achieving an HbA1c target of < 7.0%
without documented symptomatic (< 3.0 mmol/L [< 54 mg/dL])
hypoglycaemia (Responder Ratio: 1.25 [95% CI: 1.01 to 1.54])
(Table S3; see supplementary material associated with this article
online).Please cite this article in press as: Bolli GB, et al. Glycaemic control a
glargine 100 U/mL in insulin-naı¨ve people with type 2 diabetes: 12-
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Overall satisfaction with treatment, measured by the DTSQs
(possible score range 0–36), was high in both treatment groups.
The mean (SD) Total Treatment Satisfaction scores were similar in
the two groups at baseline (Gla-300, 27.2 [7.1]; Gla-100, 26.3 [7.1])
and at month 12 (32.1 [4.7] and 31.7 [5.0]). Health-related quality
of life (EQ-5D utility index score) remained stable in both
treatment groups throughout the 12-month study (data not
shown). As previously reported, fear of hypoglycaemia was very
low at baseline [10], and decreased further to month 12 in both
treatment groups. The mean (SD) total HFS-II score decreased from
0.52 (0.63) to 0.42 (0.47) in the Gla-300 group, and from 0.61 (0.68)
to 0.47 (0.53) in the Gla-100 group.
Weight change
The mean (SD) change in body weight from baseline to last on-
treatment value was small and similar in both groups: 0.97 (4.32)
kg in the Gla-300 group and 1.20 (4.16) kg in the Gla-100 group. LS
mean difference (95% CI) for Gla-300 versus Gla-100 was 0.24
(0.81 to 0.33) kg.
Adverse events
Overall, 63% of participants in both treatment groups experi-
enced an AE during the 12-month on-treatment period (Table S4;
see supplementary material associated with this article online).
The most commonly reported of these were infections (38% in
the Gla-300 group vs. 37% in the Gla-100 group), gastrointesti-
nal disorders (20% vs. 19%) and musculoskeletal disorders (17%
vs. 17%). The percentages of participants reporting injection site
reactions, treatment-emergent serious adverse events, and
treatment-emergent adverse events leading to withdrawalnd hypoglycaemia with insulin glargine 300 U/mL versus insulin
month results from the EDITION 3 trial. Diabetes Metab (2017),
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(Table S4; see supplementary material associated with this
article online). Twelve participants (four in the Gla-300 group
and eight in the Gla-100 group) were identified as experiencing
potential major adverse cardiac events over the 12-month on-
treatment period. As previously reported, one participant, in
the Gla-300 group, died as a result of a serious treatment-
emergent adverse event (worsening of atherosclerotic heart
disease) [10].
Discussion
The findings of EDITION 3 reported here are in keeping with the
sustained glycaemic control observed with Gla-100 and Gla-300
between months 6 and 12 in the EDITION 1 and 2 studies (in people
already using basal insulin, or basal plus meal-time insulin)
[8,9]. Similarly to the 12-month results of the EDITION 1 trial [8],
HbA1c levels were better sustained over 12 months with Gla-300
versus Gla-100, although the between-treatment difference was
not statistically significant in EDITION 3 (as it was in EDITION 1).
Thus, in a population of insulin-naı¨ve people with type 2 diabetes,
Gla-300 and Gla-100 provided equivalent overall glycaemic
control at 12 months, and similar to that observed at 6 months
[10]. No new safety signals were detected.
As observed over the first 6 months [10], the percentage of
participants reporting nocturnal confirmed or severe, or docu-
mented symptomatic, hypoglycaemia over 12 months was similar
or lower in the Gla-300 group versus the Gla-100 group, regardless
of the glycaemic threshold used. However, there was a lack of
statistical significance for many of the between-group differences,
at least partly due to the low overall numbers of hypoglycaemic
events in EDITION 3, as evidenced by wide confidence intervals in
the estimates of relative risk. The use of an insulin-naı¨ve study
population with a relatively low risk of hypoglycaemia [17],
presumably due to participants having greater endogenous insulin
secretion, may have contributed to the lower number of
hypoglycaemic events in EDITION 3 compared with EDITION
1 and 2, where Gla-300 did reduce the risk of hypoglycaemia,
particularly at night, compared with Gla-100. Furthermore, the
discontinuation of sulfonylureas at baseline in EDITION 3 is likely
to have lowered the occurrence of hypoglycaemia, as indirectly
suggested by the results of studies with similar design where
sulfonylureas were continued [18–20].
That Gla-300 may cause less hypoglycaemia than Gla-100 in
people who are at higher risk of events is supported by the findings
of the subgroup analyses; over 12 months people generally
considered to be at higher risk of hypoglycaemia [21,22] (those
with a lower BMI [< 30 kg/m2], and those with longer diabetes
duration [ 10 years]), experienced a significantly reduced risk of
hypoglycaemia with Gla-300 versus Gla-100 (Fig. 5). While these
exploratory results should be interpreted with caution (as
heterogeneity of treatment effect between the subgroups was
not detected), the data suggest that further investigation to
determine the potential advantages of Gla-300 in such high-risk
populations may be warranted.
The observation that statistically significant differences
between Gla-300 and Gla-100 in hypoglycaemic risk were found
for the proportion of people experiencing hypoglycaemia with
a < 3.0-mmol/L glycaemic threshold, when this was not found for
the conventional  3.9 mmol/L cut-off, may be important. In
terms of statistical power this finding is paradoxical, as the
number of people affected is smaller with the tighter cut-off, and
the confidence intervals wider (Fig. 3). One possible explanation
may be that with a population in relatively tight blood glucose
control, excursions below 4.0 mmol/L but above 3.0 mmol/L are
common, while excursions below 3.0 mmol/L are more likely toPlease cite this article in press as: Bolli GB, et al. Glycaemic control a
glargine 100 U/mL in insulin-naı¨ve people with type 2 diabetes: 12-
http://dx.doi.org/10.1016/j.diabet.2017.04.007result from a less than flat 24-hour insulin delivery, or more
erratic absorption, features that are improved with Gla-300
versus Gla-100 [5].
In EDITION 3, patient satisfaction, as measured by DTSQs, was
good in both the Gla-300 and Gla-100 treatment groups. Notably,
fear of hypoglycaemia was low at baseline and decreased further,
up to month 12, in both groups. This result is useful, given that in
some geographical regions many people may discontinue insulin
therapy shortly after starting it [23], possibly due to experience or
fear of hypoglycaemia.
The results at month 12 in EDITION 3 confirm those previously
reported at month 6 [10]. However, the possible difference in FPG
and HbA1c at month 6 (non-significant) with Gla-300 versus
Gla-100 was reversed at month 12. This result was associated with
(and likely explained by) a possibly greater dose of both Gla-300
and Gla-100 at month 12 versus month 6, with a higher dose for
Gla-300 versus Gla-100 at month 12 (+20%), compared with
month 6 (+17%). Indirectly, these differences suggest that in
EDITION 3 insulin titration was actively continued in both groups
until month 12.
In this 12-month analysis of EDITION 3, the percentage of
participants achieving an HbA1c target of < 7.0%, without hypo-
glycaemia, was higher with Gla-300 than with Gla-100 for all
hypoglycaemia categories analysed. Although often not statisti-
cally significant, these differences between the insulins are
consistent with the lower risk of confirmed (< 3.0 mmol/L) or
severe hypoglycaemia with Gla-300. These data suggest that for
insulin-naı¨ve people with diabetes beginning basal insulin therapy,
Gla-300 may enable more to reach glycaemic targets without an
increased risk of hypoglycaemia, compared with Gla-100. Further
studies in people at higher risk of hypoglycaemia are warranted to
determine if all people with type 2 diabetes may achieve similar
glycaemic targets with Gla-300 without an increased risk of
hypoglycaemia.
The higher dose of Gla-300 compared with Gla-100 required to
maintain glycaemic control over 12 months in EDITION 3 is similar
to that reported for the 12-month EDITION 1 and 2 results
[8,9]. While the reason for this dose difference remains uncertain,
it is likely that the increased dose may be explained by a longer
residence time of Gla-300 than Gla-100 in the subcutaneous depot
[5], giving the opportunity for greater enzymatic inactivation of the
glargine molecule.
In EDITION 3, a predefined time interval of 00:00–05:59 h was
used as the nocturnal window. However, hypoglycaemic events
occurred most frequently between 06:00 and 10:00, a time which
includes both a period of fasting and the post-breakfast period for
some people. This finding suggests that evening injections of long-
acting insulins may increase the risk for hypoglycaemia primarily
in the second half of the morning, and that Gla-300 reduces such a
risk versus Gla-100. As such, while the use of a 00:00–05:59 h
definition of the nocturnal window may be more specific for the
fasting nocturnal period, the midnight–10:00 h window is more
clinically relevant as it includes the time period during which the
highest number of hypoglycaemic events are reported (06:00 and
10:00 h).
Limitations of the current study include its open-label design
(due to the different pen injectors), and the fact that contact
between trial staff and participants was, as in usual clinical
practice, relatively infrequent during the extension period.
While the drop-out rates may be of note, they were not
particularly high for this kind of study. Owing to the relatively
small number of hypoglycaemic events reported, the power to
detect significant differences in hypoglycaemia risk and rates
was low. Care should also be taken when extending the current
findings to other populations, such as people with type
1 diabetes.nd hypoglycaemia with insulin glargine 300 U/mL versus insulin
month results from the EDITION 3 trial. Diabetes Metab (2017),
G.B. Bolli et al. / Diabetes & Metabolism xxx (2017) xxx–xxx8
G Model
DIABET-885; No. of Pages 8Conclusions
The 12-month results of EDITION 3 in insulin-naı¨ve people with
type 2 diabetes demonstrate achievement of glycaemic control in
people treated with Gla-300 or Gla-100, accompanied by a lower
risk of hypoglycaemia below 3.0 mmol/L (both confirmed or severe
and documented symptomatic events) for Gla-300 versus Gla-100.
In the context of similarly positive results observed in other
EDITION studies of people with type 2 diabetes [8,9], these findings
suggest that regardless of the disease stage, long-term treatment
with Gla-300 may have benefits over Gla-100.
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